Company profile for Biomea Fusion

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs including greater target selectivity, lower drug exposure and the a...
We are a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Chamberlain Building 726 Main St.Redwood City, CA 94063
Telephone
Telephone
(650) 980-9099
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/05/3200588/0/en/Biomea-Fusion-Presents-COVALENT-111-Study-Results-at-the-23rd-World-Congress-on-Insulin-Resistance-Diabetes-Cardiovascular-Disease-WCIRDC.html

GLOBENEWSWIRE
05 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197423/0/en/Biomea-Fusion-Inc-Reports-Inducement-Grant-under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197435/0/en/Biomea-Fusion-Announces-Oral-Presentation-of-Icovamenib-at-the-23rd-World-Congress-on-Insulin-Resistance-Diabetes-Cardiovascular-Disease-WCIRDC.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193352/0/en/Biomea-Fusion-to-Participate-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184390/0/en/Biomea-Fusion-to-Participate-at-Jefferies-London-Healthcare-Conference.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181272/0/en/Biomea-Fusion-Showcases-Preclinical-Advances-for-BMF-650-and-Icovamenib-with-Low-Dose-Semaglutide-at-ObesityWeek-2025.html

GLOBENEWSWIRE
05 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty